Synergistic Anti-Angiogenic Effect of Combined VEGFR Kinase Inhibitors, Lenvatinib, and Regorafenib: A Therapeutic Potential for Breast Cancer

Background: Breast cancer currently affects more than two million women worldwide, and its incidence is steadily increasing. One of the most essential factors of invasion and metastasis of breast cancer cells is angiogenesis and non-angiogenic vascularization. Lenvatinib and Regorafenib share the sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Bajbouj, Khuloud, Qaisar, Rizwan, Alshura, Mohammed A., Ibrahim, Zeinab, Alebaji, Mohamad B., Al Ani, Amenah W., Janajrah, Hanadi M., Bilalaga, Mariah M., Omara, Abdelrahman I., Abou Assaleh, Rebal S., Saber-Ayad, Maha M., Elmoselhi, Adel B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028329/
https://www.ncbi.nlm.nih.gov/pubmed/35457226
http://dx.doi.org/10.3390/ijms23084408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028329/
https://www.ncbi.nlm.nih.gov/pubmed/35457226
http://dx.doi.org/10.3390/ijms23084408

Ejemplares similares